Schizophrenia Spectrum Disorders

Pathophysiology

Altered dopaminergic signaling is implicated in psychosis, particularly salience attribution; glutamatergic and GABAergic dysfunction and distributed cortical connectivity have also been studied (Kelly & Borovicka, 2026). The disorder cannot be reduced to “excess dopamine.”

Clinical Manifestations

Diagnostic syndrome and epidemiologic patterns

Schizophrenia-spectrum illness usually begins in late adolescence or early adulthood, though onset varies (Kelly & Borovicka, 2026). Positive symptoms include hallucinations, delusions, and disorganized speech or behavior; negative symptoms include diminished expression, avolition, social withdrawal, and reduced spontaneous speech; cognitive deficits may involve processing speed, working memory, and executive function. The DSM-5-TR requires at least two qualifying active-phase symptom types, including delusions, hallucinations, or disorganized speech among them, and at least six months of overall disturbance with meaningful functional decline. The active phase typically lasts at least one month unless successfully treated; this distinguishes schizophrenia from briefer psychotic syndromes (American Psychiatric Association, 2022). Biological vulnerability is polygenic and developmental, influenced by environmental exposures, but there is no single diagnostic dopamine test or brain scan.

Diagnostic Evaluation

Operational duration and mood-psychosis differentials

Duration and the relationship between mood and psychotic symptoms help distinguish brief psychotic disorder, schizophreniform disorder, schizophrenia, and mood disorders with psychotic features. DSM-5-TR duration thresholds are at least one day but less than one month with return to premorbid function for brief psychotic disorder, at least one month but less than six months for schizophreniform disorder, and at least six months of disturbance for schizophrenia, including at least one month of active-phase symptoms (or less if successfully treated). These duration rules do not replace full symptom criteria, functional assessment, and exclusions. Psychosis confined to depressive or manic episodes favors a mood-disorder formulation, while substance effects, delirium, and neurologic disease require separate investigation (American Psychiatric Association, 2022; First, 2014; Kelly & Borovicka, 2026; Keshavan, 2025a).

Negative symptoms can be primary manifestations of illness or secondary to depression, antipsychotic adverse effects, environmental deprivation, or substance use (Kelly & Borovicka, 2026). Before escalating antipsychotics for reduced motivation or social engagement, assess depressed mood, extrapyramidal effects, sedation, and cognitive burden. This distinction changes the likelihood of benefit and the choice of psychosocial intervention.

Structured first-episode evaluation and longitudinal monitoring

Document vital signs, arousal and attention, onset, substance and medication exposure, sleep, neurologic signs, mood episode chronology, trauma/safety context, and collateral baseline information. Order focused laboratory tests according to suspected metabolic, endocrine, infectious, or toxic causes; use imaging or EEG when examination and history suggest focal or atypical neurologic disease. Screen suicidality, inability to meet basic needs, and risk of harm without equating all psychotic illness with dangerousness. Coordinate early psychosis care, housing and functional supports, family education when appropriate, and substance-use services when indicated (Kelly & Borovicka, 2026).

Track positive, negative, and cognitive symptoms separately, alongside work or school participation, patient-defined goals, and social functioning. Positive psychotic symptoms generally respond more readily to antipsychotic medication than primary negative or cognitive symptoms; persistent functional impairment is not proof that further dopamine blockade will help (Kelly & Borovicka, 2026). Monitor weight, glycemic measures, lipids, extrapyramidal and tardive symptoms, sedation, falls, prolactin-associated symptoms, and QT risk when relevant. Before concluding a trial has failed, confirm exposure, duration, adherence, medical and substance-related contributors, and the specific symptom domain that remains impaired. Clozapine is an evidence-based option for treatment-resistant schizophrenia after appropriate trials, but its benefits and monitoring burdens require individualized assessment (Kelly & Borovicka, 2026).

Differential Diagnosis

Differential based on chronology

Psychotic symptoms occurring only during a major mood episode favor a mood disorder with psychotic features rather than a primary schizophrenia diagnosis. Persistent mood-independent psychosis with major mood episodes raises a schizoaffective differential: a qualifying period of at least two weeks of delusions or hallucinations without a major mood episode must coexist with major mood episodes occupying the majority of the total active and residual illness course (Keshavan, 2025b). Acute fluctuating inattention is more typical of delirium; isolated hallucinations with preserved insight may occur with neurologic or sensory disorders. Collateral accounts of baseline function and symptom duration are often more diagnostic than the patient’s most vivid single reported experience (American Psychiatric Association, 2022; Kelly & Borovicka, 2026).

Treatment and Management

Treatment response and longitudinal monitoring

Clozapine remains an established option for treatment-resistant schizophrenia and requires monitoring for severe neutropenia as well as potentially serious cardiometabolic, cardiac, neurologic, and gastrointestinal adverse effects. The FDA eliminated the clozapine REMS program effective June 13, 2025; prescriber, patient, and pharmacy enrollment and REMS reporting are no longer required. This administrative change did not eliminate recommended absolute neutrophil count monitoring, which should follow current prescribing information. Treatment initiation and follow-up must also address myocarditis symptoms, constipation and ileus, metabolic change, sedation, seizures, and relevant interactions (U.S. Food and Drug Administration [FDA], 2025; Kelly & Borovicka, 2026).

Clinical Reasoning Priorities

Applied case: the chronology of psychosis

A patient hears threatening voices only during a sustained period of profound depressive symptoms and has never experienced hallucinations when mood was normal. Depression with psychotic features enters the differential. Another individual has sustained psychotic and disorganized symptoms without major mood episodes, raising a primary schizophrenia-spectrum formulation after medical and substance-related causes have been addressed. The timing and functional context are more informative than the dramatic content of a single hallucination. Early specialty coordination and safety assessment matter in both cases.

Related YourDNP Guides

For related clinical reasoning, see Depressive and Bipolar Mood Disorders and Neurobiology of Psychiatric Disorders.

• Back to Pathophysiology
• Rational Drug Selection

---

---

References

American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). American Psychiatric Association Publishing.

First, M. B. (2014). DSM-5 handbook of differential diagnosis. American Psychiatric Publishing.

Kelly, D. L., & Borovicka, M. (2026). Schizophrenia. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed.). McGraw Hill.

Keshavan, M. S. (2025a, July). Brief psychotic disorder. Merck Manual Professional Edition. https://www.merckmanuals.com/professional/psychiatric-disorders/schizophrenia-and-related-disorders/brief-psychotic-disorder

Keshavan, M. S. (2025b, July). Schizoaffective disorder. Merck Manual Professional Edition. https://www.merckmanuals.com/professional/psychiatric-disorders/schizophrenia-and-related-disorders/schizoaffective-disorder

U.S. Food and Drug Administration. (2025, August 27). FDA removes risk evaluation and mitigation strategy (REMS) program for the antipsychotic drug clozapine. https://www.fda.gov/drugs/drug-safety-and-availability/fda-removes-risk-evaluation-and-mitigation-strategy-rems-program-antipsychotic-drug-clozapine